MX2016003878A - A composition, a production process thereof and use of said composition for the treatment of central nervous system disorders. - Google Patents

A composition, a production process thereof and use of said composition for the treatment of central nervous system disorders.

Info

Publication number
MX2016003878A
MX2016003878A MX2016003878A MX2016003878A MX2016003878A MX 2016003878 A MX2016003878 A MX 2016003878A MX 2016003878 A MX2016003878 A MX 2016003878A MX 2016003878 A MX2016003878 A MX 2016003878A MX 2016003878 A MX2016003878 A MX 2016003878A
Authority
MX
Mexico
Prior art keywords
composition
treatment
production process
nervous system
central nervous
Prior art date
Application number
MX2016003878A
Other languages
Spanish (es)
Inventor
Alves Catalan Cláudia
De Oliveiro Rufino Marcelo
Antonio Bernes Junior Edson
Original Assignee
Aché Laboratórios Farmacêuticos S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58543671&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016003878(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aché Laboratórios Farmacêuticos S A filed Critical Aché Laboratórios Farmacêuticos S A
Publication of MX2016003878A publication Critical patent/MX2016003878A/en

Links

Abstract

A Composition, a production process thereof and use of said composition is disclosed for treatment of CNS disorders. The present invention describes novel and inventive compositions comprising neural receptor inhibitors in a composition useful for the treatment of CNS disorders, especially those associated with Alzheimer's, wherein said composition has a lower degree of friability and a higher degree of hardness than state-of-the-art compositions Known. Additionally, there is provided herein an improved process for the production of said composition, as well as its use.
MX2016003878A 2015-09-25 2016-03-23 A composition, a production process thereof and use of said composition for the treatment of central nervous system disorders. MX2016003878A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102015024749A BR102015024749A2 (en) 2015-09-25 2015-09-25 composition, production process and use of composition for treating snc disorders

Publications (1)

Publication Number Publication Date
MX2016003878A true MX2016003878A (en) 2017-03-24

Family

ID=58543671

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003878A MX2016003878A (en) 2015-09-25 2016-03-23 A composition, a production process thereof and use of said composition for the treatment of central nervous system disorders.

Country Status (3)

Country Link
BR (1) BR102015024749A2 (en)
EC (1) ECSP16012261A (en)
MX (1) MX2016003878A (en)

Also Published As

Publication number Publication date
ECSP16012261A (en) 2018-04-30
BR102015024749A2 (en) 2017-04-04

Similar Documents

Publication Publication Date Title
PH12016501307A1 (en) Compounds
MX2022004102A (en) Oligonucleotide compositions and methods of use thereof.
MX2019014974A (en) Aadc polynucleotides for the treatment of parkinson's disease.
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
PH12018502028A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
MX2018012655A (en) Compounds and methods for treating neurological and cardiovascular conditions.
TN2017000134A1 (en) 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2020006385A (en) Compositions and methods of treatment for neurological disorders comprising a dementia.
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
MX2020000523A (en) Isochroman compounds and uses thereof.
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
MX2019006495A (en) Treatment of neurological diseases.
PH12019500198A1 (en) Compounds and compositions and uses thereof
WO2018178243A3 (en) Dihydrotetrabenazine for use in the treatment a movement disorder
MY184878A (en) Compositions and methods for treating neurodegenerative diseases
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2018001592A (en) Compositions and methods for treating and preventing neurodegenerative disorders.
MY187204A (en) Process for the production of titanium dioxide, and titanium dioxide obtained thereby
MX2017006692A (en) Neurodegenerative disorders.
MX2020006140A (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions.
MX2016008968A (en) Organic compounds.